Shanghai Pharmaceuticals Holding Stock Shares Owned By Institutions
| S1R Stock | EUR 1.58 0.01 0.63% |
Shanghai Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Shanghai Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Pharmaceuticals stock.
Shanghai |
Shanghai Pharmaceuticals Holding Company Shares Owned By Institutions Analysis
Shanghai Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Shanghai Pharmaceuticals Shares Owned By Institutions | 32.12 % |
Most of Shanghai Pharmaceuticals' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 32.12% of Shanghai Pharmaceuticals Holding are shares owned by institutions. This is 28.05% lower than that of the Healthcare sector and 62.15% lower than that of the Medical Distribution industry. The shares owned by institutions for all Germany stocks is 18.08% higher than that of the company.
Shanghai Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Pharmaceuticals' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shanghai Pharmaceuticals by comparing valuation metrics of similar companies.Shanghai Pharmaceuticals is rated below average in shares owned by institutions category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 8.94 B | |||
| Shares Outstanding | 919.07 M | |||
| Shares Owned By Insiders | 22.00 % | |||
| Shares Owned By Institutions | 32.12 % | |||
| Price To Earning | 6.59 X | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 215.82 B | |||
| Gross Profit | 28.41 B | |||
| EBITDA | 10.73 B | |||
| Net Income | 5.09 B | |||
| Cash And Equivalents | 23.68 B | |||
| Cash Per Share | 8.33 X | |||
| Total Debt | 7.16 B | |||
| Debt To Equity | 0.67 % | |||
| Current Ratio | 1.23 X | |||
| Book Value Per Share | 17.90 X | |||
| Cash Flow From Operations | 5.06 B | |||
| Earnings Per Share | 0.23 X | |||
| Price To Earnings To Growth | 2.42 X | |||
| Number Of Employees | 47.06 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 9.17 B | |||
| Total Asset | 163.44 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 2.74 % | |||
| Net Asset | 163.44 B | |||
| Last Dividend Paid | 0.42 |
About Shanghai Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.